0
0
New Delhi, May 13:
In a major leap for reproductive medicine, Swedish researchers have unveiled a simple, rapid oral swab test that could dramatically improve the success rates of in vitro fertilization (IVF) worldwide. Developed by a team at Lund University and led by Professor Yvonne Lundberg Giwercman, the test promises to personalize hormone therapy for women undergoing IVF-potentially increasing pregnancy rates, reducing health risks, and lowering costs for healthcare systems.
A Persistent Challenge in IVF
IVF, a process where eggs are matured via hormone therapy, fertilized in a lab, and then implanted into the uterus, has long been plagued by uncertainty in selecting the optimal hormone regimen. Women are typically prescribed either biological or synthetic hormones to stimulate egg maturation, but mismatched therapy can lead to failed cycles and, in some cases, severe side effects requiring emergency care. Currently, around 75% of IVF attempts fail, and up to 20% of women experience significant side effects.
The Science Behind the Swab
The new oral swab test, which delivers results in under an hour, is designed to identify a woman’s genetic variant of the follicle-stimulating hormone receptor (FSHR) gene. This gene plays a crucial role in how the body responds to hormone therapy during IVF. By matching the hormone type-biological or synthetic-to the patient’s genetic profile, clinicians can now tailor treatment to maximize the chances of a successful pregnancy and minimize adverse reactions.
The test is straightforward: a swab from the inside of the cheek is analyzed, and the result is displayed visually in either pink or yellow, indicating the most suitable hormone therapy. This innovation replaces time-consuming and costly gene sequencing, making personalized IVF accessible and affordable.
Clinical Impact and Global Promise
The clinical study included 1,466 women undergoing IVF in Sweden, with 475 randomly assigned to different hormone therapies and the rest serving as controls. Results showed a striking 38% increase in live birth rates among women whose hormone therapy matched their FSHR gene variant, compared to those who received standard treatment. This translates to approximately 110 additional babies born per 1,000 IVF patients-a significant improvement with the potential to reshape fertility care worldwide.
Professor Giwercman expressed optimism about the test’s impact:
“Our hope is that this will reduce the risk of suffering for women, increase the number of successful treatments, and cut costs for taxpayers. Our goal is for the test to be available by the start of 2026,” she said.
Next Steps
The research team has filed for a patent and established a company, Dx4Life AB, to commercialize the test, aiming for market availability by early 2026. Experts believe this breakthrough could become a new standard in IVF clinics, not just in Sweden but globally, offering hope to millions of couples facing infertility.
Disclaimer:
This article is based on the latest scientific research and statements from the involved researchers. The oral swab test is currently pending regulatory approval and broader clinical implementation. Individuals considering IVF or fertility treatments should consult with qualified healthcare professionals for personalized advice.
Citations:
